INC Research‘s Kendle acquisition vaulted the North Carolina clinical research organization into the CRO industry’s top five and according to CEO James Ogle, helps the company become a global player. Ogle spoke with Outsourcing Pharma, a British publication that covers the CRO industry. Audio of the Outsourcing Pharma interview can be heard here. In the […]
INC Research‘s $232 million acquisition of Ohio clinical research organization Kendle (NASDAQ:KNDL) is complete. Raleigh, North Carolina-based INC announced completion of the all-cash deal Tuesday after the close of the financial markets. The combined, privately held company will operate as INC Research led by INC’s CEO James Ogle, along with his INC management team. The […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
INC Research‘s new CFO revealed a lofty goal for the clinical research organization shortly after joining the Raleigh, North Carolina company in February. Within five years, David Gill said, INC aims to be one of the top five CROs in the industry. Privately held INC’s $232 million acquisition of the larger Cincinnati, Ohio-based Kendle International […]
Cincinnati-based contract research organization Kendle International (Nasdaq:KNDL) has solved its “acquire-or-be-acquired” dilemma. Kendle agreed to sell itself to Raleigh, North Carolina-based CRO INC Research for $232 million, according to a statement from the companies. The selling price of $15.25 per share represents a 60.5 percent premium over Kendle’s closing share price on Wednesday. Kendle’s board […]
A strange thing happened on Kendle International‘s (NASDAQ:KNDL) most recent quarterly earnings conference call. An analyst asked CEO-to-be Steve Cutler if he planned to make any significant changes once he takes the company’s reins from current CEO and founder Candace Kendle. Bearing in mind that Kendle had just announced a $9 million loss — its […]
Contract research organization Kendle International (NASDAQ: KNDL) saw its stock tumble 12 percent a day after it announced a $9 million fourth-quarter loss. Despite a raft of less-than-stellar numbers, new CEO Steve Cutler said he doesn't foresee any big changes in the short or medium term.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Change is in the air at contract research organization Kendle International (NASDAQ:KNDL), which announced that the company's husband-and-wife co-founders would take on reduced roles.
Market volatility continues to hurt Kendle International Inc. (NASDAQ: KNDL) as the contract research organization (CRO) saw its profits plummet 82 percent in the third quarter.
Updated 4:20 p.m. on Thursday, May 6, 2010. Contract research organization (CRO) Kendle International (NASDAQ: KNDL) is beginning to see a turnaround in its business as negative trends that have been affecting its drug- and therapy-developing clients taper off. Some securities analysts recently have said Kendle is in a tough spot — too small to […]
Kendle International seems to be caught in the awkward space between the biopharmaceutical industry’s first and second tiers, according to securities analysts quoted by the Business Courier of Cincinnati. For one analyst, that means Kendle should buy or be bought. For another, it means Kendle should acquire other contract research organizations (CROs) so it can […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Contract research organization Kendle International Inc.‘s Chinese affiliate has received a certification that the company says highlights the quality and consistency of its operations in China. The company said KendleWits, its Chinese arm, is the first global contract research organization (CRO) to achieve ISO 9001:2008 certification in the country, according to a statement from Kendle. […]
Kendle International, the clinical research organization in Cincinnati, has received approval from Indian authorities to open an operations center in a Special Economic Zone in the Ahmedabad-Gandhinagar Knowledge Corridor by mid-April.
Shares of Cincinnati-based Kendle International Inc. have plunged 19 percent over the two days since the clinical research organization released a weak earnings report and said it would continue to cut jobs. Kendle shares fell to $17.03 on the NASDAQ Stock Exchange Friday, down $3.95 from Wednesday's pre-earnings release close of $20.98.
Continuing industry flux caused Kendle International's net income to fall 31 percent to $2.3 million, or 16 cents a diluted share, in the fourth quarter, and 34 percent to $15.2 million, or $1.02 a diluted share, in 2009. Revenue fell 19 percent to $130.9 million in the fourth quarter, and 19 percent to $551.9 million, for the year.
Despite a weak economy, high unemployment and ongoing stories about the federal corruption probe of Cuyahoga County government, a poll shows voters overwhelmingly approve the renewal of an upcoming human services levy, which, in part, would fund MetroHealth Medical Center, WKYC-TV reported.